Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes - PubMed
4 hours ago
- #APOBEC
- #Immunotherapy
- #Breast Cancer
- Breast cancer (BRCA) significantly impacts women's survival quality and life expectancy, with rising incidence and mortality rates.
- Study investigates APOBEC family genes' genomic characteristics across BRCA subtypes and their influence on mutation profiles.
- APOBEC mutation enrichment scores (APMs) are significantly elevated in BRCA, with HER2+ showing the highest and TNBC the lowest.
- Correlations found between APMs and tumor mutational burden (TMB), suggesting differential immune microenvironment interactions.
- APMs associated with DNA damage response pathways, impacting treatment strategies.
- APOBEC mutagenesis-related prognostic risk score (AMrs) predicts immunotherapy response in BRCA subtypes (TNBC, Luminal, HER2+).
- Specific agents combined with anti-PD-1 therapy boost effectiveness and transform tumor immunological environment in mice.
- Synergistic approach led to reduced tumor volume and increased cytotoxic T cell density in experiments.
- APOBEC family genes' role in BRCA heterogeneity highlights potential as biomarkers for personalized therapy.